Plain-English translation of NCT06908694 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โPhase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is studying whether semaglutide, a medication originally used for weight loss and diabetes, is safe and helpful for men with prostate cancer who are undergoing hormone therapy. The study will track how the medication affects weight, blood pressure, blood sugar, cholesterol, and prostate-related markers over one year. Researchers want to understand whether this treatment can help reduce heart disease risks that sometimes develop during prostate cancer hormone therapy.
Men receiving hormone therapy for prostate cancer often experience weight gain and increased risks for heart disease. This medication has been shown to help with weight management and may offer heart-protective benefits, but it hasn't been thoroughly tested in men with prostate cancer to see if it's safe and effective in this specific group.
If you join this trial, you'll receive weekly injections of the medication, starting at a low dose and gradually increasing over four months to find the dose that works best for you. You'll have an in-person visit at the start, a phone check-in at one month, and then in-person visits at three months, six months, and one year. At each visit, the research team will check your weight, blood pressure, blood sugar, cholesterol, and other health markers to see how the treatment is working.
AI-generated summary from trial data ยท Sep 18, 2026 ยท Not medical advice
Canada
Phase
Post-approval monitoring
Sponsor
Hamilton Health Sciences Corporation
Collaborators
McMaster University
Enrollment target
~20 participants
Started
July 2025
Primary completion
October 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in September 2026.